Clinical Trials Logo

Clinical Trial Summary

This study aims to slow down disease progression, reduce postoperative complications and decrease retreatment frequency in subjects with proliferative diabetic retinopathy (PDR) by administering a single subretinal injection of RRG001 gene therapy after vitrectomy.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT06412224
Study type Interventional
Source Tianjin Medical University Eye Hospital
Contact
Status Recruiting
Phase Early Phase 1
Start date December 20, 2023
Completion date December 31, 2028

See also
  Status Clinical Trial Phase
Completed NCT04692688 - Study of the Safety and Efficacy of APX3330 in Diabetic Retinopathy Phase 2